Fatty liver disease symptoms: Visible fluid build-up in the body is a warning sign
FATTY liver disease symptoms: One in five Britons are in the early stages of the condition. Do you fit the risk profile? Overweight men in their 50s are most likely to be affected, but it can happen to anyone. (Source: Daily Express - Health)
Source: Daily Express - Health - January 24, 2021 Category: Consumer Health News Source Type: news

Fatty liver disease symptoms: Red palms could be sign of ‘aggressive’ form of condition
FATTY liver disease, also known as nonalcoholic fatty liver disease, can lead to serious health complications if left untreated. Red palms can be a sign of an "aggressive" form of the condition - nonalcoholic steatohepatitis. (Source: Daily Express - Health)
Source: Daily Express - Health - January 23, 2021 Category: Consumer Health News Source Type: news

CT spots patients with high-risk liver disease
The Fibrosis-4 (FIB-4) index and multiple CT findings can identify patients...Read more on AuntMinnie.comRelated Reading: Can AI screen for nonalcoholic fatty liver disease? Ultrasound options abound for diagnosing liver disease Quantitative imaging biomarkers show promise for NASH MRI protocol could replace biopsy for pediatric liver disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 23, 2021 Category: Radiology Source Type: news

Fatty liver disease symptoms: The visual warning sign on your legs, ankles and feet
FATTY liver disease is a common condition caused by the storage of extra fat in the liver. Non-alcoholic fatty liver disease is one of the main types of fatty liver disease. Swelling in the legs, ankles, feet or tummy is associated with the advanced stage of NAFLD. (Source: Daily Express - Health)
Source: Daily Express - Health - January 22, 2021 Category: Consumer Health News Source Type: news

CT identifies patients with high-risk nonalcoholic fatty liver disease (NAFLD)
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology, Fibrosis-4 and multiple CT findings can identify patients with high-risk nonalcoholic fatty liver disease--advanced fibrosis or cirrhosis, that is--though the presence of nonalcoholic steatohepatitis remains elusive on CT. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fatty liver disease: The two warning signs of the condition found in your abdomen
FATTY liver disease is a common condition caused by the storage of extra fat in the liver. Occasionally the condition can cause liver damage. Experiencing either abdominal pain or swelling could mean you're at risk. (Source: Daily Express - Health)
Source: Daily Express - Health - January 21, 2021 Category: Consumer Health News Source Type: news

Fatty liver disease symptoms: The colour of your eyes could indicate you have the disease
FATTY liver disease is more likely to affect people who have diabetes, high cholesterol and/or high blood pressure. If you're at risk of the condition, how would you know if you had it? What are the symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - January 20, 2021 Category: Consumer Health News Source Type: news

Fatty liver disease symptoms: Two physical warning signs of the dangerous condition
FATTY liver disease is one of the most common hidden conditions. What are the physical symptoms to look out for indicating your risk and that your diet needs to change immediately? (Source: Daily Express - Health)
Source: Daily Express - Health - January 18, 2021 Category: Consumer Health News Source Type: news

Green med diet cuts non-alcoholic fatty liver disease by half - Ben-Gurion U. study
(American Associates, Ben-Gurion University of the Negev) Overall, the green MED diet produced dramatic reductions in fatty liver. NAFLD prevalence dropped from 62% at baseline to 31.5% in the green Mediterranean group, down to 47.9% in the Mediterranean group and 54.8% in the healthy dietary regimen group. Addressing this common liver disease by targeted lifestyle intervention might promote a more effective nutritional strategy. This Ben-Gurion University of the Negev clinical trial demonstrates an effective nutritional tool for NAFLD beyond weight loss (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 18, 2021 Category: Biology Source Type: news

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question, Lancet Gastroenterology and Hepatology
Amongst other points, article highlights that patients with cirrhosis are likely to have attenuated immune responses with vaccination. Nonetheless, given the high COVID-19-related mortality in these patients, it remains important to prioritise vaccination in this subgroup. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 13, 2021 Category: Consumer Health News Source Type: news

SARS-CoV-2 Infection in Patients With Normal or Abnormal Liver SARS-CoV-2 Infection in Patients With Normal or Abnormal Liver
This paper summarizes what we know about SARS-CoV-2 in patients with liver disease, as well as its impact on the healthy liver. How should management of liver patients change in the COVID-19 era?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
[10-22-2015] The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause severe liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Fatty Liver Disease-A Multifaceted Disease With Multiple Names? Fatty Liver Disease-A Multifaceted Disease With Multiple Names?
In this commentary, the authors suggest that a more precise terminology for NAFLD is needed, with a more granular view on subcategories of NASH to guide preventive and therapeutic measures.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Triclosan worsens fatty liver disease in mice
The antibacterial compound, found in consumer products and some drinking water, worsened liver health in diabetic mice fed a high-fat diet. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - January 6, 2021 Category: Environmental Health Source Type: news

HEALTH NOTES: Surge in patients admitted to hospital for alcohol-related liver disease
Doctors believe the problem could be endemic, with recent analysis showing the number of people drinking excessively doubled between February and March. (Source: the Mail online | Health)
Source: the Mail online | Health - January 2, 2021 Category: Consumer Health News Source Type: news

ALBI Likely Bests MELD-Na for Outcomes Prediction Across Surgeries ALBI Likely Bests MELD-Na for Outcomes Prediction Across Surgeries
The Albumin-Bilirubin score more accurately predicted outcomes in patients undergoing pulmonary, elective colorectal and adrenal operations than the Model for End Stage Liver Disease-sodium.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2020 Category: Consumer Health News Tags: General Surgery News Source Type: news

Pittsburgh-based LyGenesis receives FDA clearance for new drug application
Pittsburgh-based LyGenesis Inc. received U.S. Food and Drug Administration clearance for its Investigational New Drug application, according to a news release. LyGenesis was founded to develop cell therapies to enable organ regeneration. With this new application, LyGenesis will move forward with a Phase 2a study on the safety, tolerance and efficacy of its novel cell therapy for end stage liver disease, according to the release.  LyGenesis also recent ly finalized $11 million in private financing… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 31, 2020 Category: American Health Authors: Julia Mericle Source Type: news

Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in India
Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patients who do not consume alcohol or take it in insignificant amounts, but have risk factors such as overweight or obesity, diabetes mellitus (high blood sugar), hypertension (high blood pressure) or dyslipidemia (abnormal blood lipids). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 30, 2020 Category: Pharmaceuticals Source Type: news

In liver, a stressed cell can be bad news for its neighbors
(Harvard T.H. Chan School of Public Health) When a stressed liver cell starts communicating with its neighbors, it can send stress signals to neighboring cells, causing significant problems that can lead to fatty liver disease and metabolic disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 18, 2020 Category: Biology Source Type: news

Childhood intervention can prevent 'deaths of despair'
(Duke University) Mortality rates among young adults are rising in the US due in part to 'deaths of despair' -- preventable deaths from suicide, drug overdoses and alcohol-related liver disease. An intensive childhood intervention program called Fast Track could help reduce these deaths by reducing risky behaviors in adolescence and young adulthood, finds new research from Duke University and the Conduct Problems Prevention Research Group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news

Primary Biliary Cholangitis: Controversies and Perspectives Primary Biliary Cholangitis: Controversies and Perspectives
Review the diagnosis, natural history, and management of primary biliary cholangitis, a rare progressive immune-mediated liver disease.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Zydus Cadila gets USFDA Fast Track Designation for Saroglitazar
Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease - primary biliary cholangitis (PBC). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2020 Category: Pharmaceuticals Source Type: news

Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 8, 2020 Category: Drugs & Pharmacology Source Type: news

The dangers of herbal weight loss supplements: a case report of drug-induced liver injury secondary to Garcinia cambogia ingestion - McCarthy RE, Bowen DG, Strasser SI, Mckenzie C.
Drug induced liver injury (DILI) should be suspected in patients presenting with unexplained liver disease. Recent data from the US Drug Induced Liver Injury Network reports 16% of acute liver failure cases are causally related to dietary supplements. Up t... (Source: SafetyLit)
Source: SafetyLit - December 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Sensor can detect scarred or fatty liver tissue
(Massachusetts Institute of Technology) MIT engineers have now developed a diagnostic tool, based on nuclear magnetic resonance (NMR), that could be used to detect both fatty liver disease and liver fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 2, 2020 Category: International Medicine & Public Health Source Type: news

One man ’s liver transplant story: How a routine visit saved this patient’s life
When Eric Browne ’s routine physical revealed elevated enzymes in his liver, he was referred to Atrium Health Liver Care Clinic in Greensboro, North Carolina, a satellite clinic of Atrium Health Carolinas Medical Center’s liver disease and transplant program. There, he was able to get the specialized liver care he needed. Learn more about liver transplant care at Atrium Health. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 1, 2020 Category: Health Management Authors: Atrium Health Source Type: news

One man ’s liver transplant story: How a routine visit saved this patient’s life
When Eric Browne ’s routine physical revealed elevated enzymes in his liver, he was referred to Atrium Health Liver Care Clinic in Greensboro, North Carolina, a satellite clinic of Atrium Health Carolinas Medical Center’s liver disease and transplant program. There, he was able to get the specialized liver care he needed. Learn more about liver transplant care at Atrium Health. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 1, 2020 Category: Biotechnology Authors: Atrium Health Source Type: news

Mayo Clinic Q and A: Y-90 therapy offers many benefits in treatment of liver cancer
DEAR MAYO CLINIC: My father has had chronic liver disease. Recently, he was diagnosed with liver cancer. His doctor mentioned Y-90 as one treatment option. What is Y-90, and is it safe? ANSWER: Chronic liver disease is the most common risk factor for the development of liver cancer, and patients frequently face both conditions at the time [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 25, 2020 Category: Databases & Libraries Source Type: news

Study: gut hormones' regulation of fat production abnormal in obesity, fatty liver disease
(University of Illinois at Urbana-Champaign, News Bureau) Gut hormones play an important role in regulating fat production in the body. One key hormone, released a few hours after eating, turns off fat production by regulating gene expression in the liver, but this regulation is abnormal in obesity, researchers at the University of Illinois Urbana-Champaign found in a new study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news

Cirrhosis Cases Rising Among Women in North America
MONDAY, Nov. 23, 2020 -- Cirrhosis disease burden in women has increased substantially since 2000, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held virtually... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Antimicrobial soap additive worsens fatty liver disease in mice
(University of California - San Diego) Triclosan, an antimicrobial found in many soaps and other household items, worsens fatty liver disease in mice fed a high-fat diet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 23, 2020 Category: International Medicine & Public Health Source Type: news

NAFLD Prevalence Rising Among Children but Many Undiagnosed NAFLD Prevalence Rising Among Children but Many Undiagnosed
The incidence of nonalcoholic fatty liver disease (NAFLD) is rising among children, but not all youth with obesity are getting recommended screening, a study in California suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2020 Category: Consumer Health News Tags: Pediatrics News Source Type: news

2009 to 2018 Saw Increase in Incidence of NAFLD in Children
THURSDAY, Nov. 19, 2020 -- From 2009 to 2018, there was an increase in the incidence of nonalcoholic fatty liver disease (NAFLD) among children, although many still remain undiagnosed, according to a study published online Nov. 19 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news

Maraxilibat reduces debilitating itching in children with Alagille syndrome
(Baylor College of Medicine) On behalf of Childhood Liver Disease Research Network (ChiLDReN), Texas Children's Hospital and Baylor College of Medicine researchers report that prolonged treatment with Maraxilibat resulted in clinically meaningful improvements in debilitating itching (pruritus) and related quality of life outcomes in children with Alagille syndrome. The novel pharmacological approach addresses a major unfulfilled therapeutic need to control severe and relentless itching in pediatric patients with Alagille syndrome. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2020 Category: International Medicine & Public Health Source Type: news

Lipid Profiles Distinguish Obese and Nonobese NAFLD Patients Lipid Profiles Distinguish Obese and Nonobese NAFLD Patients
Both obese and nonobese individuals can develop nonalcoholic fatty liver disease, and lipid profiles were effective predictors in both groups, based on data from a cross-sectional study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Mayo Clinic Q & amp;A podcast: Cardiometabolic diseases increase COVID-19 risk
An estimated 47 million Americans are living with cardiometabolic diseases, according to the American College of Cardiology. Cardiometabolic diseases are interrelated conditions that include cardiovascular diseases, such as heart disease, stroke, and hypertension, as well as metabolic diseases, such as Type 2 diabetes, obesity and nonalcoholic fatty liver disease. Patients with cardiometabolic diseases have a [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 13, 2020 Category: Databases & Libraries Source Type: news

Echosens launches liver disease solution in U.S.
Ultrasound technology developer Echosens has launched FibroScan 630 Expert...Read more on AuntMinnie.comRelated Reading: Echosens technology used for liver fibrosis study Echosens taps new president for North America Echosens brings FibroScan to Henry Ford Echosens gets FDA clearance for FibroScan (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 9, 2020 Category: Radiology Source Type: news

Liver disease and alcohol — is binge drinking to blame?
Yale Medicine emergency doctors are concerned that binge drinking at young ages is leading to a rise in earlier cases of liver disease. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 4, 2020 Category: Universities & Medical Training Source Type: news

Dietary supplement may help in the treatment of fatty liver
(University of Jyv ä skyl ä - Jyv ä skyl ä n yliopisto) A recent study by researchers at the University of Jyv ä skyl ä was successful in partially preventing fatty liver disease in rats. Rats with fatty liver disease were fed with a dietary supplement that is known to increase the growth of good bacteria in the gut. Simultaneous with the increased abundance of the bacteria, the liver fat content decreased significantly. In addition, preliminary results from a human study seem promising. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 4, 2020 Category: International Medicine & Public Health Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Eating less suppresses liver cancer due to fatty liver
(Shinshu University) Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan. In order to change this unfortunate state of affairs, it is important to improve the prognosis of non-alcoholic fatty liver disease. Fatty liver is often improved through eating less, getting more exercise, and reducing body weight. The research group posed the question, " Can eating less also suppress liver cancer caused by fatty liver? " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2020 Category: Cancer & Oncology Source Type: news

The road to uncovering a novel mechanism for disposing of misfolded proteins
(Baylor College of Medicine) The discovery of the cause of a rare liver disease in babies led to uncovering a novel cellular mechanism for disposing of misfolded proteins that has implications for neurodegenerative conditions of older age (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2020 Category: International Medicine & Public Health Source Type: news

Start-up awarded grant to develop contrast agent for early detection of liver disease
(Georgia State University) Inlighta Biosciences, LLC, a start-up company led by Jenny Yang, Regents' Professor of Chemistry at Georgia State University, has been awarded a National Institute of Health grant to accelerate development of a magnetic resonance imaging contrast agent to detect liver fibrosis, formation of scar tissue in the liver caused by alcoholic and non-alcoholic fatty liver disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news

Predictors of Mortality and Disease Progression in NAFLD Predictors of Mortality and Disease Progression in NAFLD
This study aimed to elucidate the factors associated with mortality and disease progression in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a real-world cohort.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Chronic Liver Disease and Outcomes of Patients With COVID-19 Chronic Liver Disease and Outcomes of Patients With COVID-19
This study found that one in five patients hospitalized with COVID-19 had underlying chronic liver disease. What was the impact of CLD on COVID-19 symptoms and outcomes?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

NAFLD Closely Tied to Diabetes Risk NAFLD Closely Tied to Diabetes Risk
Patients with non-alcoholic fatty-liver disease (NAFLD) have a higher risk of diabetes, and the more severe the disease the greater the risk, according to new research.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 8, 2020 Category: Pathology Tags: Gastroenterology News Source Type: news